SAFETY AND EFFICACY OF ROSUVASTATIN FOR HYPERLIPIDEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND ABOVE  by Yuto, Jun et al.
Kidney Res Clin Pract 31 (2012) A16–A96A864
LOW BMI IS THE RISK OF CARDIO-VASCULAR MORTALITY WITHOUT
PROGRESSION OF CKD
Tae Yamamoto, Mariko Miyazaki, Masaaki Nakayama, Tasuku Nagasawa,
Hiroshi Sato, Toshinobu Sato, Sadayoshi Ito
Tohoku University, Sendai, Japan.
The paradoxical risk of BMI on mortality is known in CKD as well in dialysis
populations, but studies of CVD risk in CKD including underweight is limited.
We hypothesized lean CKD increase the CVD risk, contributing different factors
from obese. 2,676 CKD patients recruited from 11 outpatients’ hospitals. BMI
and estimated GFR (eGFR) were calculated, and change of eGFR and CVD
mortality during 2 years were collected. Patients were divided by BMI under
cut off value of normal, thus 7% grouped in lean subjects (BMI o18.5). Systolic
blood pressure (sBP), albumin, hemoglobin, age and prevalence of diabetes
were lower in lean BMI group compared to other subjects. However CVD
history, urinary protein, baseline eGFR and smoking didn’t differ between the
groups. The lean BMI increased signiﬁcantly the risk of CVD mortality, in spite
of low prevalence of comorbidities and young age in unadjusted model (HR
2.38, 95%CI 1.49-5.21, po0.01). This signiﬁcance remained after adjusted for
CVD risk factors, such as primary disease of CKD, age, sex, smoking, albumin,
cholesterol, sBP and eGFR. On the other hand, BMI was not associated with the
decline rate of eGFR.We concluded that BMI less than 18.5 was an independent
predictor of CVD, and that BMI did not effect on CKD progression rate in
Japanese CKD.
http://dx.doi.org/10.1016/j.krcp.2012.04.597274
SURVIVAL AND RISK FACTORS ASSOCIATED WITH MORTALITY IN
DIABETIC PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL
DIALYSIS IN SOUTHERN CHINA
Xiao Yang, Chunyan Yi, Xinghui Liu, Qunying Guo, Xueqing Yu
Department of Nephrology, The First Afﬁliated Hospital of Sun Yat-sen
University, Guangzhou, China
This study aimed to analyze the survival and the risk factors associated
with mortality in diabetic CAPD patients in Southern China. This single-
center prospective cohort study enrolled all incident CAPD patients from
Jan 2006 to Dec 2009 and followed-up until Dec 2011.Survival in diabetic
and non-diabetic CAPD patients and the risk factors on mortality in the
diabetic CAPD subjects were evaluated. Among 841 incident CAPD subjects
in this study, 193 patients (22.9%) were diabetes. The mean vintage of
CAPD was 29.4715.5 months. Shorter patient survival time was found in
diabetic patients compared to that of non-diabetic ones (po0.01). The 1-,
3- and 5-year patient survival rates were 90%, 64% and 40% in diabetes and
95%, 88% and 75% in non-diabetes, respectively (po0.01). There was no
signiﬁcant difference in the death-censored technique survival time
between diabetic and non-diabetic patients. The 1-, 3- and 5-year
technique survival rates were 96%, 88% and 86% in diabetic, while 99%, 93%
and 87% in non-diabetic patients, respectively. Diabetic CAPD patients that
died during the follow-up period had older age(63.4710.5 vs.58.6710.4
yrs, po0.01), higher proportion of cardiovascular diseases (CVD)(64.9% vs.
47.1%, po0.05), higher level of hsCRP [5.1(1.511.7) vs. 1.8 (0.87.2)]
mg/L, po0.01), but lower levels of haemoglobin (95.5720.2 vs.
103.4719.2g/L, po0.01), serum albumin (33.774.0 vs.35.374.9g/L,
po0.05) and 24h urine output [600(300813) vs. 800(5001100]ml/d,
po0.01) compared to the survivors. The presence of CVD, advanced age,
higher glycosylated haemoglobin, lower hemoglobin and serum albumin at
the initiation of PD were independent predictors of death in diabetic
patients.It was concluded that survival of diabetic CAPD patients is not as
good as that of non-diabetic patients in Southern Chinese patients, but
better than those reported by other previous studies. Better management
of modiﬁable risk factors such as hyperglycaemia, anemia and
hypoalbuminemia may improve outcomes of diabetic PD patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.598275
SAFETY AND EFFICACY OF ROSUVASTATIN FOR HYPERLIPIDEMIA IN
PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND ABOVE
Jun Yuto, Yosuke Ehara, Kazuhiko Shibata, Tamio Iwamoto, Gen Yasuda,
Mari Katsumata, Yuichiro Yamamoto, Nobuhito Hirawa
Yokohama City University Center Hospital, Yokohama, JapanThe frequency of hypertriglyceridemia is high in CKD patients, but few
medications are available for controlling this lipid parameter when renal
insufﬁciency advances. We evaluated the safety and efﬁcacy of long-term
treatment with rosuvastatin, one of the strong statins for hypercholesterolemic
control, on lipid abnormalities in patients with CKD stage 3 and above. The
protocol consisted of a 4-week run-in period and a 48-week treatment phase
with rosuvastatin. Inclusion criteria were CKD stage 3 and above with serum
low-density lipoprotein (LDL) cholesterol levels above 100 mg/dL and
triglyceride levels above 150 mg/dL. Patients received 2.5 to 5.0 mg
rosuvastatin daily. Lipid parameters and myolysis-related indicators were
measured. Forty-nine patients (29 men and 20 women aged 61 7 9 years,
serum creatinine levels above 1.5 mg/dL) were enrolled in the study.
Rosuvastatin signiﬁcantly decreased (P/0.05) serum LDL cholesterol from 163
7 39 to 126 7 31 mg/dL and apolipoprotein B from 151 7 36 to 108 7
24mg/dL at 4 weeks and maintained these parameters at low levels.
Rosuvastatin also signiﬁcantly decreased (P ¼ 0.001) serum triglyceride levels
from 194 7 43mg/dL at baseline to 160 7 51mg/dL at 48 weeks. High-
density lipoprotein (HDL) cholesterol concentrations did not change from
baseline (56 7 16mg/dL) to 48 weeks of treatment (57 7 17mg/dL).
However, LDL/HDL ratio decreased signiﬁcantly (P ¼ 0.036) from 3.4 7 0.7 to
2.2 7 0.9, which approached the target level (2.0). During the rosuvastatin
treatment period, serum creatine kinase, aldolase, and myoglobin
concentrations did not change. In conclusion, rosuvastatin treatment improved
serum triglyceride level as well as the LDL/HDL ratio in hyperlipidemic patients
with CKD stage 3 and above, without serious adverse effects, suggesting that
rosuvastatin is useful to control not only hypercholesterolemia but also
hypertriglyceridemia in CKD patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.599276
EFFECT OF SARPOGRELATE ON FISTULA PATENCY OF FOREARM
ARTERIOVENOUS ANASTOMISIS IN UREMIC PATIENTS
Jun Yuto, Yosuke Ehara, Kazuhiko Shibata, Tamio Iwamoto, Gen Yasuda,
Keisuke Yatsu, Mari Katsumata, Nobuhito Hirawa
Yokohama City University School of Medicine, Kanagawa, Japan
Subcutaneous arteriovenous ﬁstula in the forearm is a common vascular
access for hemodialysis. However, primary failure of native ﬁstula occurs
because of either thrombosis formation within the ﬁrst several weeks after
surgery or immature vein dilatation. To evaluate the effect of platelet inhibition
on ﬁstula thrombosis and maturation failure, we used an antiplatelet agent,
sarpogrelate hydrochloride, in our study. The study was designed as an open-
label, parallel, prospective, randomized study for 8 weeks, comparing patients
receiving sarpogrelate 300 mg/day (sarpogrelate group, n¼33) with controls
receiving no medication (n¼46). The primary outcome was ﬁstula patency
failure determined by pulse Doppler ultrasound examination of the
arteriovenous ﬁstula performed 8 weeks after surgery. Pulse wave velocity was
also measured to determine the ankle brachial pressure index (ABI). The drug
was well-tolerated and did not increase bleeding events during the 8-week
study period. In the sarpogrelate group, patency failure occurred in 1 of 33
patients (3.0%), and the occlusion rate was signiﬁcantly lower (P¼0.001) than
that in the control group (3 of 46 patients; 6.5%). Average blood ﬂow rate in the
sarpogrelate group was 5467174 mL/min, and was signiﬁcantly higher
(P¼0.036) than 4487183mL/min in the control group. However, the diameter
of the shunt vessel in the sarpogrelate group was 5.271.3 mm, which was not
different from 5.170.6 mm in the control group. The Vmax was not
signiﬁcantly different between two groups (1.0170.56 m/sec in the
sarpogrelate group and 0.8970.66 m/sec in the control group). In all patients
(n¼79), blood ﬂow correlated with ABI (r¼0.34, P¼0.045). Our results suggest
that sarpogrelate reduces the frequency of ﬁstula patency failure. Sarpogrelate
may maintain ﬁstula patency, which is necessary for hemodialysis, by
increasing ABI.
http://dx.doi.org/10.1016/j.krcp.2012.04.600
